Skip over navigation
Directory
Directory Search
Jobs
Job Search
Post a Job
Patient
Patient Resources
Drug Development
History
Genealogy
Toons & Teasers
About
Advertising
Home
Quick Links
Directory
Job Search
Toons & Teasers
Advertising
LifeScienceHistory.com - Check us out on Instagram
Industry News
Search Articles:
Mirati Therapeutics announces dosing of first patient in phase 1/2 clinical trial
Mirati Therapeutics announced that it has dosed the first patient in a Phase 1/2 clinical trial of MRTX849, an investigational KRAS G12C inhibitor for patients with advanced solid tumors that harbor KRAS G12C mutations.
January 15, 2019
More...
Email This Page
to a Friend
Print This
Page